Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...
Short jail stays for minor crimes turn deadly when filth and a lack of care let infections run out of control, a USA TODAY ...
16hon MSN
The White House wants to eliminate ‘gender ideology’ and ‘trans ideology.’ What does that mean?
The terms “gender ideology” and “transgender ideology,” have become ubiquitous — in government documents and policy announcements, in mass media and in online disputes.
Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics(NASDAQ:CDTX), increasing its position value by approximately $167.48 ...
Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results